Sandra Muschiol

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

Journal: EBioMedicine

Published: November 12, 2025

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID.

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID.

Journal: EBioMedicine

Published: May 01, 2024

Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses.

Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses.

Journal: The Lancet. Infectious diseases

Published: September 01, 2023

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.

Journal: Journal of hematology

Published: May 14, 2023

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID.

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID.

Journal: EBioMedicine

Published: April 03, 2023

Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.

Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.

Journal: Haematologica

Published: February 13, 2023

Persistence of salivary antibody responses after COVID-19 vaccination is associated with oral microbiome variation in both healthy and people living with HIV.

Persistence of salivary antibody responses after COVID-19 vaccination is associated with oral microbiome variation in both healthy and people living with HIV.

Journal: Frontiers in immunology

Published: October 25, 2022

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies.

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies.

Journal: The Lancet. Infectious diseases

Published: September 19, 2022

Evasion of neutralising antibodies by omicron sublineage BA.2.75.

Evasion of neutralising antibodies by omicron sublineage BA.2.75.

Journal: The Lancet. Infectious diseases

Published: July 19, 2022

Membrane particles evoke a serotype-independent cross-protection against pneumococcal infection that is dependent on the conserved lipoproteins MalX and PrsA.

Membrane particles evoke a serotype-independent cross-protection against pneumococcal infection that is dependent on the conserved lipoproteins MalX and PrsA.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 01, 2022

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.

Journal: Blood

Published: April 27, 2022

NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.

NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.

Journal: Molecular medicine (Cambridge, Mass.)

Published: January 13, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026